32 research outputs found
Towards understanding the role of sialylation in melanoma progression
Aberrant expression of sialic acids or altered linkage types is closely associated with malignant phenotype and metastatic potential, and can have prognostic significance in human cancer. The present study was undertaken to evaluate whether expression of sialylated derivatives on melanoma cell surface is associated with tumour progression. Four cell lines (WM1552C, WM115, IGR-39 and WM266-4) were used in the study. Cell surface expression of sialic acids was evaluated by flow cytometry with the use of Maackia amurensis and Sambucus nigra lectins. Moreover, adhesion and migration potential of melanoma cells and involvement of sialic acids in these processes were analysed. We have demonstrated that WM266-4 cells have a significantly higher level of α2,3-linked sialic acid residues than other cells, whereas IGR-39 cells had lower expression of α2,6-linked sialic acids. The adhesion efficiencies of WM1552C and WM115 cells were significantly lower than that of IGR-39 and WM266-4 cells. In contrast, WM266-4 cells repaired scratch wounds at least twice as fast as other cells. Melanoma cell adhesion to fibronectin in the presence of Sambucus nigra agglutinin (SNA) was reduced only in IGR-39 and WM266-4 cells, whereas the impact of Maackia amurensis agglutinin (MAA) on this process was much more important. Migration efficiency of melanoma cells was reduced more strongly in the presence of MAA than SNA. In conclusion, our results show that melanoma progression is associated with the increased expression of α2,3-linked sialic acids on the cell surface and these residues could promote melanoma cell interaction with fibronectin
A pilot study on improve the functioning of extensive green roofs in city centers using mosses
Most of environmental benefits of green roofs results from the presence of a vegetation layer. However vascular plants quickly die in harsh urban conditions. This paper presents research involving moss species appearing spontaneously on green roofs in cities to test whether we can create a vegetation layer with simplifi ed structure introducing that moss. It was checked using two transplant methods and three models of such roofs. Research evidenced that moss Ceratodon purpureus Hedw. is able to survive on green roofs in cities with high efficiency and can develop after transplant on roofs with a simple structure. Maximum weight of the moss layer during the year did not exceed 7.0 kg·m–2
Treatment of severe mitral regurgitation with MitraClip system — a single-centre study
Introduction. MitraClip (MC) is a catheter-based device to treat mitral regurgitation (MR). This method uses a transseptal approach and is based on the creation of a double orifice mitral valve by suturing of the middle scallops of the mitral valve’s leaflets.
Aim. The aim of the study was to assess the effectiveness of MC method in treating patients with severe MR. We analysed MR severity, patient’s clinical condition evaluated by New York Heart Association (NYHA) functional class, and the function of the left ventricle evaluated by Left Ventricle Ejection Fraction (LVEF).
Methods. A retrospective single-centre study with patients hospitalised at the Department of Cardiology and Internal Medicine in Bydgoszcz. All diagnosed with severe MR and treated by performing MC procedure in the time period from August 2010 to December 2014. The following data from medical history (NYHA class) and echocardiography examinations (MR severity and LVEF) were analysed in three time points: before, right after the procedure, and after the follow-up period (four weeks since discharge).
Results. The studied group consisted of 11 patients — 8 male, 3 female, aged 64.4 ( ± 10.2) years, treated with MC. All of the three analysed parameters improved relevantly as a result of the evaluated procedure. The percentage of patients classified as NYHA class III/IV presents as follows: 90% before the procedure, 55% after MC implantation (ns), and 44% after the follow-up period (p = 0.01). All patients suffered from severe-to-moderate (3+) and severe (4+) MR before the procedure. After implantation only 9% (ns) were still classified with 3+/4+ MR, and after the follow-up this percentage reached 18% (p = 0.0005). We observed relevant changes of LVEF. The average LVEF at baseline was 27.9 ± 2%, which increased to 29.6 ± 2% (ns) after the MC implantation and 34 ± 7% (p = 0.02) after the follow-up.
Conclusion. MC therapy is effective in patients with severe symptomatic MR with congestive heart failure and decreased LVEF. It reduces MR severity both acutely and after the follow-up period and improves NYHA class and LVEF.
Variability of prasugrel antiplatelet effect in patients with acute coronary syndrome
Background. Many reports have demonstrated excessive variability in response to clopidogrel, the most commonly used P2Y12 receptor antagonist. Clopidogrel resistant patients are at increased risk of cardiovascular (CV) events. Prasugrel is a new P2Y12 inhibitor that provides greater and faster platelet inhibition and reduces CV events more effectively than clopidogrel. The aim of this study was to evaluate the variability and efficacy of prasugrel antiplatelet activity in patients presenting with acute coronary syndrome (ACS).
Materials and methods. The study was designed as a prospective, single-center, non-randomized, observational trial. Platelet reactivity (PR) was assessed with the VeryfyNow assay three times during hospitalization in forty-two patients undergoing percutaneous coronary intervention (PCI) for ACS and treated with standard doses of prasugrel.
Results. Platelet aggregation with prasugrel displayed relatively high variability. The platelet aggregation was lowest on the 3rd day of the treatment at 4 p.m. and was significantly different from the measurements obtained on the 3rd and 4th day in the morning (6.0 v. 8.5 U; p = 0.0005 and 6.0 v. 36.5 U; p < 0.00001, respectively), with the latter two differing significantly from each other (p = 0.002). All participants were successfully treated with prasugrel achieving PR < 208 PRU in each measurement, whereas 42.9–80.9% (depending on sampling point) of patients presented very low platelet activity. The subgroups of stable and persistent low PR included a higher percentage of active smokers (73.3 v. 40.7%; p = 0.04 and 80.0 v. 43.8%; p = 0.04, respectively).
Conclusions. Prasugrel treatment is associated with high variability of PR. Nonetheless, prasugrel is a highly effective antiplatelet drug. Active smoking may predispose to strong and stable on-prasugrel platelet inhibition.
Adrenal “nonadenoma” — clinical characteristics and risk of malignancy
Introduction: There is an increasing number of adrenal tumours discovered incidentally during imaging examinations performed for many different indications. Based on imaging results, it is possible to differentiate benign from malignant adrenal masses, although there is still a number of equivocal imaging findings. Our study presents 77 cases of adrenal tumours in which imaging was inconclusive and the final diagnosis was stated only after surgery and histopathological examination.
Material and methods: Retrospective data analysis: 77 cases of indeterminate adrenal tumours with a presumptive diagnosis of “nonadenoma” in patients operated within a 16-year period (2004–2019). None of the patients had a history of malignancy, and all tumours were hormonally inactive. On contrast-enhanced computed tomography (CT), the native density of all tumours was higher than 10 Hounsfield Units (HU), and the absolute percentage washout (APW) and relative percentage washout (RPW) were lower than 60% and 40%, respectively.
Results: The most common findings were adrenal adenoma (25.9%), macronodular adrenal hyperplasia (16.9%), ganglioneuroma (15.6%), and haemorrhage with posthaemorrhagic changes (13%). In total, there were 12 various histopathological diagnoses in this group. There were only 2 (2.6%) malignant (adrenal cancer and leiomyosarcoma) and 3 (3.9%) potentially malignant (pheochromocytoma) lesions in this group.
Conclusions: It is often impossible to make a correct diagnosis in a clinical setting until it is histologically verified. “Nonadenoma” adrenal tumours constitute a heterogeneous group including very rare pathologies. The risk of malignancy in indeterminate adrenal tumours is relatively low.
Pancreatic neuroendocrine neoplasms — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)
W niniejszej publikacji przedstawiono zaktualizowane zalecenia dotyczące diagnostyczno-terapeutycznego postępowania w nowotworach neuroendokrynnych trzustki (PNEN) zaproponowane przez Polską Sieć Guzów Neuroendokrynnych. Zawierają one nowe dane uzyskane w latach 2013–2016, które albo potwierdziły wcześniejsze wytyczne, albo doprowadziły do zmian lub utworzenia dodatkowych zaleceń. W diagnostyce duże znaczenie mają badania biochemiczne, obrazowe (anatomiczne i czynnościowe), jak również rozpoznanie histopatologiczne, które determinuje postępowanie z chorymi na PNEN i musi być potwierdzone badaniem immunohistochemicznym. Terapia PNEN wymaga współpracy wielodyscyplinarnej grupy doświadczonych specjalistów zajmujących się nowotworami neuroendokrynnymi. Leczenie chirurgiczne jest podstawową metodą postępowania w wielu przypadkach. Dalsza terapia wymaga wielokierunkowego działania, dlatego omówiono zasady bioterapii, leczenia radioizotopowego, celowanego leczenia molekularnego oraz chemioterapii.This article presents updated diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine tumours (PNEN), proposed by the Polish Network of Neuroendocrine Tumours. The guidelines contain new data received in the years 2013–2016, which confirm previous recommendations, and have led to modification of previous guidelines or have resulted in the formulation of new guidelines. Biochemical and imaging (anatomical and functional) tests are of great importance in diagnostics, as well as histopathological diagnosis to determine the management of PNEN patients, but they must be confirmed by an immunohistochemical examination. PNEN therapy requires collaboration among the members a multidisciplinary team of specialists experienced in the management of these neoplasms. Surgery is the basic form of treatment in many cases. Further therapy requires a multidirectional procedure; therefore, the rules of biotherapy, peptide receptor radionuclide therapy, molecular targeted therapy, and chemotherapy are discussed
Colorectal neuroendocrine neoplasms — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)
Nowotwory/guzy neuroendokrynne (NEN/NET) jelita grubego są rozpoznawane coraz częściej, szczególnie guzy odbytnicy. To zjawisko jest najprawdopodobniej związane z powszechnym wykonywaniem kolonoskopii przesiewowych. Coraz więcej przemawia za tym, że NEN odbytnicy i okrężnicy to dwie odrębne choroby. Nowotwory neuroendokrynne odbytnicy są najczęściej zmianami niewielkich rozmiarów, cechują się niskim lub umiarkowanym stopniem złośliwości histologicznej, dobrym rokowaniem i większość z nich kwalifikuje się do leczenia endoskopowego. Natomiast NEN okrężnicy to często nowotwory agresywne, niskozróżnicowane, o złej lub niepewnej prognozie, wymagające operacji. Zasady postępowania z tymi chorymi stale się zmieniają. Opierając się na najnowszym piśmiennictwie oraz ustaleniach wypracowanych na spotkaniu roboczym Polskiej Sieci Guzów Neuroendokrynnych (grudzień 2016 r.) w pracy uzupełniono i uaktualniono dane i wytyczne postępowania dotyczące NEN jelita grubego, opublikowane w Endokrynologii Polskiej 2013; 64: 494–504.Neuroendocrine neoplasms/tumours (NENs/NETs) of the large intestine are detected increasingly often, especially rectal tumours, which is probably associated with the widespread use of screening colonoscopy. There is a growing body of evidence supporting the thesis that the NENs of the rectum and the NENs of the colon are two different diseases. Rectal NENs are usually small lesions, of low to moderate histological malignancy, associated with good prognosis, and most may be treated endoscopically. NENs of the colon, however, are often aggressive, poorly differentiated, associated with a poor or uncertain prognosis, and require surgical treatment. The management guidelines regarding these groups of patients are constantly changing. On the basis of the recent literature data and conclusions reached by the working meeting of the Polish Network of Neuroendocrine Tumours (December 2016), this study completes and updates the data and management guidelines regarding colorectal NENs published in Endokrynologia Polska 2013; 64: 358–368.
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)
Postęp w diagnostyce i leczeniu nowotworów neuroendokrynnych (NEN), opublikowanie wyników nowych randomizowanych badań klinicznych oraz powstanie nowych zaleceń ENETS skłoniło ekspertów skupionych w Polskiej Sieci Guzów Neuroendokrynnych do uaktualnienia opublikowanych w 2013 roku zaleceń dotyczących postępowania w nowotworach neuroendokrynnych. W niniejszym artykule przedstawiono zalecenia ogólne postępowania w NEN będące wynikiem ustaleń ekspertów uczestniczących w III Konferencji Okrągłego Stołu pt. „Diagnostyka i leczenie nowotworów neuroendokrynnych układu pokarmowego: rekomendacje polskie w świetle aktualnych zaleceń europejskich”, która odbyła się w Żelechowie koło Warszawy w grudniu 2016 roku. Korzystając z bogatego doświadczenia ośrodków zajmujących się tymi nowotworami, mamy nadzieję, że udało nam się wypracować najbardziej optymalny sposób postępowania u chorych z NEN, uwzględniający najnowsze osiągnięcia medycyny, który będzie mógł być skutecznie realizowany w naszym kraju. W kolejnych częściach tego opracowania przedstawiono zasady postępowania w: NEN żołądka i dwunastnicy (z uwzględnieniem gastrinoma), trzustki; jelita cienkiego i wyrostka robaczkowego oraz jelita grubego.Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), the published results of new randomised clinical trials, and the new guidelines issued by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Network of Neuroendocrine Tumours to update the 2013 guidelines regarding management of these neoplasms. We present the general recommendations for the management of NENs, developed by experts during the Third Round Table Conference — Diagnostics and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European recommendations, which took place in December 2016 in Żelechów near Warsaw. Drawing from the extensive experience of centres dealing with this type of neoplasms, we hope that we have managed to develop the optimal management system, applying the most recent achievements in the field of medicine, for these patients, and that it can be implemented effectively in Poland. These management guidelines have been arranged in the following order: gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs
Neuroendocrine neoplasms of the small intestine and appendix — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)
W pracy przedstawiono uaktualnione polskie zalecenia postępowania z chorymi na nowotwory neuroendokrynne (NEN) jelita cienkiego i wyrostka robaczkowego. Jelito cienkie, a w szczególności jelito kręte, należą do najczęstszych lokalizacji tych nowotworów. Większość z nich to nowotwory wysokozróżnicowane i wolno rosnące; rzadko są to raki neuroendokrynne. Ich objawy mogą być nietypowe, a rozpoznanie opóźnione albo przypadkowe. Zapalenie wyrostka robaczkowego jest najczęściej pierwszą manifestacją NEN o tym umiejscowieniu. Typowe objawy zespołu rakowiaka występują u około 20–30% pacjentów z NEN jelita cienkiego z przerzutami odległymi. Jedną z głównych przyczyn zgonu u pacjentów z zespołem rakowiaka są choroby serca — rakowiakowa choroba serca. W diagnostyce laboratoryjnej najbardziej przydatne jest oznaczenie stężenia chromograniny A, badanie stężenia kwasu 5-hydroksyindolooctowego jest pomocne w diagnostyce zespołu rakowiaka. W obrazowaniu stosuje się ultrasonografię, tomografię komputerową, rezonans magnetyczny, kolonoskopię, wideoendoskopię kapsułkową, enteroskopię dwubalonową, scyntygrafię receptorów somatostatynowych. Szczegółowe badanie histologiczne jest kluczowe dla właściwego rozpoznania i leczenia chorych z NEN jelita cienkiego i wyrostka robaczkowego. Leczeniem z wyboru jest postępowanie chirurgiczne, radykalne lub paliatywne. W leczeniu farmakologicznym czynnych i nieczynnych hormonalnie NEN jelita cienkiego i wyrostka robaczkowego podstawowe znaczenie mają długodziałające analogi somatostatyny. U chorych z NET jelita cienkiego w okresie uogólnienia z progresją w trakcie leczenia SSA, z wysoką ekspresją receptorów somatostatynowych należy rozważyć w pierwszej kolejności leczenie radioizotopowe, a następnie terapie celowane — ewerolimus. Po wyczerpaniu powyższych dostępnych terapii w wybranych przypadkach można rozważyć chemioterapię. Przedstawiono także zalecenia odnośnie do monitorowania chorych.This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20–30% of patients suffering from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed histological report is crucial for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA treatment, with good expression of somatostatin receptors, the first-line treatment should be radioisotope therapy, while targeted therapies, such as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered